Navigation Links
BD Biosciences Launches New Cell Analyzer for Complex Multicolor Experiments in Disease and Drug Development Research
Date:6/1/2009

Special Order BD LSRFortessa(TM) Benchtop Flow Cytometry System Supports up to Five Lasers and 18 Colors Simultaneously

SAN JOSE, Calif., June 1 /PRNewswire/ -- BD Biosciences, a segment of BD (Becton, Dickinson and Company), announced today the launch of the new special order BD LSRFortessa(TM) cell analyzer, a powerful compact system that provides life science researchers with the ability to conduct complex multicolor flow cytometry experiments.

"Our special order research products program combines the knowledge gained from decades of working closely with leading researchers and excelling in manufacturing," said Jay Glasscock, President, Cell Analysis, BD Biosciences. "It allows us to work closely with customers to configure a BD LSRFortessa system that meets their exact specifications."

The BD LSRFortessa system offers power and flexibility in a benchtop footprint that is significantly smaller than the industry leading BD(TM) LSR II cell analyzer. It is the only compact cell analyzer that supports up to five lasers. Researchers can choose from 30 positions for detectors and 11 laser wavelengths and multiple power options to detect up to 18 colors simultaneously. Working with BD Biosciences' flow cytometry experts, laboratories can configure a system that meets their precise assay requirements.

"Space is at a premium in most research settings, leading many labs to compromise system power and performance because of space limitations," said Glasscock. "The new BD LSRFortessa system eliminates the need for that sacrifice by addressing researchers' growing analytical needs and helping to maximize lab space utilization at the same time."

The BD LSRFortessa system is the newest addition to the proven line of BD(TM) LSR cell analyzers. The original BD LSR II system supports up to seven lasers and has been the preferred tool of life science researchers worldwide working in core, academic, pharmaceutical and biotechnology laboratories.

For more information about the BD LSRFortessa cell analyzer, as well as the complete BD LSR product line, please visit: http://www.bdbiosciences.com/lsr.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit http://www.bd.com.


'/>"/>
SOURCE BD-Becton Dickinson
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
2. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
3. Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
4. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
5. Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update
6. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
7. Anaptys Biosciences Raises Over $33 Million in Series B Financing
8. YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS
9. Pressure BioSciences, Inc. Reports Third Quarter 2007 Financial Results and Provides Business Update
10. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
11. Regado Biosciences to Present at 19th Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
(Date:6/24/2016)... Norcross, Georgia (PRWEB) , ... June 24, 2016 ... ... Year” awards today at the Clinical Decision Making in Emergency Medicine conference in ... who have authored journal articles published in Emergency Medicine Practice and ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, ... economy by obtaining investment capital for emerging technology companies. SCP has delivered ... already resulted in more than a million dollars of capital investment for five ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... for human induced pluripotent stem (iPS) cells and other difficult to transfect cells, ... Cloning Medium. The PluriQ™ G9™ Gene Editing System is a complete ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
Breaking Medicine Technology: